On March 17, 2021, the Prime Minister approved the Program to develop the pharmaceutical industry, domestically produced medicinal herbs to 2030, with a vision to 2045. The program has set the goal of bringing the pharmaceutical industry in The country has achieved a high level of development, reaching level 4 according to the classification scale of the World Health Organization (WHO), with a market value in the top 3 in ASEAN. This is a favorable condition for many pharmaceutical enterprises to not only maintain the domestic market but also create momentum to enter the period of deeper integration, conquering consumers with global standards. DHG Pharma is a typical example.
During the past 47 years, DHG Pharma has always been one of the leading brands in the supply of international quality pharmaceuticals and healthcare products. During its development, DHG Pharma constantly improves product quality by increasing the number of production lines meeting international standards. In addition, DHG Pharma also “shakes hands” with a strategic partner, Taisho Pharmaceutical Group (Japan’s leading pharmaceutical company), to transfer technology from process to product quality to produce products. invention drugs, drugs of high economic value.
Most recently, in April, with the transfer of production technology from Taisho Group, DHG Pharma officially produced and distributed Counterpain – Skin Pain Relief Cream in Vietnam market. This is a product that has been on the international market for nearly 50 years, trusted by Southeast Asian consumers.
Mr. Tran Duy Hung – Marketing Director of Hau Giang Pharmaceutical said that Counterpain products manufactured by a leading pharmaceutical company in Vietnam combined with Japanese production technology will help Vietnamese consumers easily find and buy and buy products. Use peace of mind, no longer have to worry about the origin and quality of the product.
According to the report of Vietnam Report (Vietnam Assessment Report Joint Stock Company), the growth prospect of the pharmaceutical industry in 2022 will have many positive signals. The room for the domestic market and export of pharmaceuticals and health care products is still very large. Market research firm BMI Research (USA) also forecasts that the size of Vietnam’s pharmaceutical market will reach $7.7 billion in 2021 and $16.1 billion in 2026, with a compound growth rate of up to 11 percent. % in VND and will continue to be in the group of 20 countries with the strongest and most stable growth in the world.
Besides, VIRAC and EvaluatePharma said that the compound growth rate of the world drug market in the period 2020 – 2026 is about 7.4% and sales in 2026 will reach 1.39 billion USD, much higher than the rate. 2.7% in the period 2012 – 2019. This is room for new suppliers, including Vietnam, to increase their contribution to the global market.
By taking steps in line with the trend of international integration, with investment in researching new drugs and expanding drug production lines to meet international standards of the drug and functional food market, DHG Pharma confidently places the 2022 revenue target is over 4,200 billion VND.
With increasing position and efforts in many different segments, DHG Pharma is increasingly enhancing the image of one of the pharmaceutical enterprises with the heart and vision in comprehensive care of the Vietnamese people’s health. Male.
at Blogtuan.info – Source: Eva.vn – Read the original article here